Pharmaceutics:介孔结构的锶取代的羟基磷灰石-CAO-CaCO3纳米纤维可作为药物输送载体

2018-10-12 MedSci MedSci原创

羟基磷灰石(HAp)是主要的无机成分,是骨和牙齿的重要组成部分。由于其优异的生物相容性、生物活性和骨传导性,HAp被广泛用作骨替代物,细胞载体和治疗基因或药物载体。最近,许多研究表明,锶取代的羟基磷灰石(SrHAp)不仅可以增强骨生成,还可以抑制间充质干细胞中的脂肪形成。 本研究中,研究人员通过传统的基于模板的方法成功合成了中孔SrHAp,发现其具有比SrHAp更好的药物装载和释放效率。在该

羟基磷灰石(HAp)是主要的无机成分,是骨和牙齿的重要组成部分。由于其优异的生物相容性、生物活性和骨传导性,HAp被广泛用作骨替代物,细胞载体和治疗基因或药物载体。最近,许多研究表明,锶取代的羟基磷灰石(SrHAp)不仅可以增强骨生成,还可以抑制间充质干细胞中的脂肪形成。

本研究中,研究人员通过传统的基于模板的方法成功合成了中孔SrHAp,发现其具有比SrHAp更好的药物装载和释放效率。在该研究中,使用溶胶-凝胶法然后静电纺丝制造具有中孔结构的锶-取代的羟基磷灰石-CaO-CaCO 3纳米纤维(mSrHANFs)。

X射线衍射分析表明,随着Sr的掺杂量增加,mSrHANFs中CaO和CaCO 3的含量减少。扫描电子显微镜(SEM)显示mSrHANF的平均直径为约200~300nm。N 2吸附-脱附等温线表明mSrHANFs具有介孔结构,平均孔径约为20~25nm。此外,mSrHANFs具有优异的载药效率,可以延缓四环素(TC)的突释,从而维持抗菌活性超过3周。

因此,mSrHANF或可作为骨组织工程中的药物载体。

原始出处:

Tsai SW, Yu WX, et al., Fabrication and Characterization of Strontium-Substituted Hydroxyapatite-CaO-CaCO₃ Nanofibers with a Mesoporous Structure as Drug Delivery Carriers. Pharmaceutics. 2018 Oct 8;10(4). pii: E179. doi: 10.3390/pharmaceutics10040179.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2018-12-12 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2018-11-16 爆笑小医
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2019-01-12 mei539
  7. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2018-11-24 shanyongle
  8. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2018-10-14 villahu
  9. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1787536, encodeId=18ac1e87536f0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 12 16:33:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996221, encodeId=26cd1996221f4, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Nov 16 08:33:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664837, encodeId=a27e166483e16, content=<a href='/topic/show?id=78dd2529262' target=_blank style='color:#2F92EE;'>#介孔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25292, encryptionId=78dd2529262, topicName=介孔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9b025850974, createdName=luckyshitiancai_42705692, createdTime=Sat Jun 08 16:33:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635688, encodeId=9e9d163568800, content=<a href='/topic/show?id=1059e743357' target=_blank style='color:#2F92EE;'>#纳米纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77433, encryptionId=1059e743357, topicName=纳米纤维)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64fe22519052, createdName=1249883fm19暂无昵称, createdTime=Thu Aug 29 17:33:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908473, encodeId=590719084e324, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 28 00:33:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645459, encodeId=8e97164545947, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sat Jan 12 02:33:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655903, encodeId=3f18165590302, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Sat Nov 24 11:33:00 CST 2018, time=2018-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460749, encodeId=3e321460e4925, content=<a href='/topic/show?id=668b96e72d9' target=_blank style='color:#2F92EE;'>#锶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96772, encryptionId=668b96e72d9, topicName=锶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21b6366000, createdName=villahu, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541645, encodeId=491a1541645af, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575197, encodeId=93f315e51978a, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Sun Oct 14 03:33:00 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2018-10-14 lfyang